Who will be able to enter the biosimilars market?

A recent article at Reuters looks at the difficulty many could face entering the biosimilars market. Ludwig Burger states that he believes due to the difficulties of entering the market, it will be limited to a small circle of specialist companies. Currently, the only successful biosimiars manufactured are human growth hormones, but the next step will probably look towards therapeutic antibodies. Biosimilars, although generic versions of biologics, will only present the market with 20-30% discounts, but will see sales growth in terms of 2-3 times faster than the other generics on the market. Read the full article here.

So, now we want to hear from you. What do you think about the battle over biosimilars?

IIR’s 2nd Annual Business of Biosimilars conference delivers effective strategies to navigate scientific, regulatory, economic, and legal challenges you face to remain competitive in commercializing your biosimilar portfolio in the United States and abroad.

Share this article with your social network, just click below to share now!

Share |